How to Get Belsomra (Suvorexant) in Montana

What Suvorexant Is and Why It Requires a Prescription

Suvorexant belongs to a class called dual orexin receptor antagonists (DORAs), which block the wake-promoting neuropeptides orexin-A and orexin-B from binding to OX1R and OX2R receptors 1. The FDA approved Belsomra in August 2014 for adults with insomnia marked by difficulty falling asleep, staying asleep, or both 2. Because suvorexant carries a Schedule IV controlled-substance designation under the Controlled Substances Act, every dispensing requires a valid prescription from a DEA-registered provider 3.

The key phase III program included two randomized, double-blind trials (Study 1, N=1,021; Study 2, N=1,009) showing that suvorexant 15 mg and 20 mg significantly reduced subjective time to sleep onset and increased total sleep time versus placebo at both one month and three months 1. A 12-month safety extension found no evidence of rebound insomnia or withdrawal upon discontinuation 4. These efficacy and safety data form the clinical basis for prescribing in Montana and elsewhere.

Montana law permits any physician (MD or DO), nurse practitioner, or physician assistant holding valid DEA registration and state prescriptive authority to write a Schedule IV prescription 5. No collaborative practice agreement is required for Montana NPs who have completed the state's independent practice pathway.

Step-by-Step: Getting a Belsomra Prescription in Montana

The fastest route for most Montana residents starts with a telehealth visit. Montana's Telehealth Access Act allows prescribers to evaluate and prescribe Schedule IV medications via synchronous audio-video encounters without a prior in-person visit 6. A typical workflow looks like this: schedule a consultation, complete a sleep intake questionnaire, attend a live video visit, and receive an electronic prescription sent directly to your pharmacy.

During the visit, expect the prescriber to screen for obstructive sleep apnea using tools like the STOP-Bang questionnaire, because the American Academy of Sleep Medicine (AASM) recommends ruling out untreated sleep-disordered breathing before initiating any hypnotic 7. If your STOP-Bang score is 3 or higher, the clinician may order a home sleep apnea test before writing the prescription.

Standard pre-prescribing labs are minimal. No blood work is FDA-mandated for suvorexant, but clinicians often check a basic metabolic panel and thyroid-stimulating hormone (TSH) to exclude metabolic causes of insomnia 8. The entire telehealth-to-pharmacy timeline in Montana typically spans 2 to 5 business days, depending on whether prior authorization is needed.

For patients who prefer in-person care, primary care clinics, sleep medicine practices, and psychiatric offices across Montana all prescribe Belsomra. Rural patients in eastern Montana, where specialist density is low, often find telehealth the more practical option.

Montana Medicaid, Commercial Insurance, and Prior Authorization

Montana Medicaid does not currently list Belsomra on its preferred drug list for insomnia. Patients enrolled in the Medicaid program face a non-preferred status, and step-therapy requirements typically mandate trial and failure of at least one generic hypnotic (such as zolpidem or trazodone) before an exception request can be submitted 9.

Commercial plans in Montana vary. Blue Cross Blue Shield of Montana and Pacific Source, two of the state's largest carriers, generally cover suvorexant as a non-preferred brand with prior authorization. The standard prior authorization packet requires three pieces of documentation: a confirmed insomnia diagnosis (ICD-10 G47.00 or G47.09), evidence of inadequate response or intolerance to at least one first-line agent, and a clinical note explaining why suvorexant is medically necessary over generic alternatives 10.

Dr. Michael Sateia, lead author of the AASM clinical practice guideline for pharmacologic treatment of chronic insomnia, has stated: "Orexin receptor antagonists represent a mechanistically distinct option for patients who have not responded to or cannot tolerate conventional hypnotics" 7.

Prior authorization turnaround in Montana averages 48 to 72 hours for electronic submissions. If the initial request is denied, Montana's insurance code allows a single-level expedited appeal that insurers must resolve within 72 hours for urgent prescriptions.

Cost Without Insurance and Savings Programs

The average retail cash price for 30 tablets of Belsomra 20 mg in Montana pharmacies ranges from $380 to $420, a figure consistent with national brand-tier pricing for Schedule IV DORAs. Merck offers a manufacturer savings card that can reduce the out-of-pocket cost to as low as $0 per fill for commercially insured patients, with a maximum annual benefit that varies by plan year 2.

For uninsured patients, two options can lower costs significantly. First, Merck's patient assistance program provides free medication to qualifying individuals with household incomes below 400% of the federal poverty level. Second, licensed 503A compounding pharmacies in Montana can prepare suvorexant formulations (such as custom-dose capsules) when a prescriber writes a patient-specific prescription, though compounded versions are not AB-rated equivalents of the branded product 11.

A cost-effectiveness analysis published in the Journal of Clinical Sleep Medicine found that DORAs, including suvorexant, showed favorable cost-per-QALY ratios compared with benzodiazepine receptor agonists when accounting for reduced fall risk in adults over 65 12.

Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Montana has approximately 220 retail pharmacies with active DEA registrations capable of dispensing Schedule IV substances. National chains like Walgreens and Albertsons stock Belsomra, and most independent pharmacies can order it within 24 hours through their primary wholesaler.

Mail-order pharmacy is another route. Express Scripts, CVS Caremark, and OptumRx all ship Schedule IV medications to Montana addresses. A 90-day supply through mail order often reduces per-tablet cost by 15% to 25% compared with monthly retail fills, making it a practical choice for patients on stable, long-term therapy 13.

Montana's Board of Pharmacy licenses 503A compounding facilities under state and federal guidelines. These pharmacies can compound suvorexant into alternative dosage forms (liquid suspensions, lower-dose capsules) when a prescriber documents a clinical need that the commercially available 5 mg, 10 mg, 15 mg, or 20 mg tablets do not meet 11. Compounded suvorexant must be dispensed pursuant to a patient-specific prescription and cannot be distributed across state lines unless the pharmacy also holds a 503B outsourcing facility registration with the FDA.

Clinical Considerations: Dosing, Interactions, and Monitoring

The FDA-approved starting dose is 10 mg taken once nightly, no more than 30 minutes before bedtime, with at least 7 hours of intended sleep remaining 2. If 10 mg is well tolerated but insufficiently effective, the dose can be increased to 20 mg. The 5 mg tablet exists for patients taking moderate CYP3A inhibitors (diltiazem, erythromycin, fluconazole), where the recommended maximum is 5 mg per night 2.

Suvorexant is contraindicated in patients with narcolepsy and should be used with caution in those with moderate hepatic impairment, where clearance is reduced by approximately 25% 2. Co-administration with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) is not recommended 14.

A pooled safety analysis of over 3,000 patients across the suvorexant clinical program reported that the most common adverse events were somnolence (7% vs. 3% placebo), headache, and dizziness 4. Next-day driving impairment was observed at the 20 mg dose in some subjects, prompting the FDA to recommend that patients taking 20 mg use caution with morning driving until they know how the drug affects them 3.

Compared with the Z-drugs (zolpidem, eszopiclone), suvorexant shows a different adverse-event profile. A systematic review and network meta-analysis of 154 randomized trials (N=44,089) published in The Lancet found that DORAs had lower rates of next-day residual sedation than benzodiazepine receptor agonists while maintaining comparable sleep-onset improvements 15.

The AASM practice guideline conditionally recommends suvorexant for sleep-maintenance insomnia in adults, citing moderate-quality evidence 7.

How Suvorexant Compares to Lemborexant

Montana patients sometimes ask whether suvorexant or lemborexant (Dayvigo) is the better DORA. Both drugs target OX1R and OX2R, but lemborexant has a shorter half-life (approximately 17 hours vs. 12 hours for suvorexant), which may translate to less next-morning residual effect in some patients 16.

A head-to-head polysomnographic study (SUNRISE-1, N=1,006) compared lemborexant 5 mg and 10 mg against placebo in adults aged 55 and older, finding significant improvements in wake after sleep onset 16. No direct randomized comparison between suvorexant and lemborexant exists in the published literature as of May 2026, so prescribing decisions rely on indirect evidence, patient response history, and insurance formulary position.

In Montana, formulary preference between the two DORAs varies by plan. Patients denied one DORA on prior authorization may have a straightforward path to approval for the other.

Transferring an Existing Belsomra Prescription to Montana

Patients relocating to Montana from another state can transfer a suvorexant prescription if the original prescription has remaining refills and was written within the past six months. Montana Board of Pharmacy rules allow inter-state transfer of Schedule IV prescriptions between pharmacies, though the receiving pharmacist must verify the prescription with the originating pharmacy before dispensing.

An alternative for new Montana residents: establish care with a Montana-licensed prescriber via telehealth, bring documentation of your treatment history (including prior prescription records and sleep study results if available), and obtain a new prescription. This approach avoids the occasional delays that occur when pharmacies in different states use incompatible electronic transfer systems.

Montana participates in the Prescription Drug Monitoring Program (PDMP), and dispensing pharmacists are required to check the PDMP before filling any Schedule IV prescription 17. This check typically adds no more than a few minutes to the dispensing process.

Cognitive Behavioral Therapy for Insomnia: The Recommended First Line

Both the AASM and the American College of Physicians (ACP) recommend cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before any pharmacotherapy 18. CBT-I delivered through digital platforms is particularly relevant for Montana residents in rural areas where in-person behavioral sleep specialists are scarce.

A meta-analysis of 20 randomized trials (N=1,902) found that digital CBT-I reduced insomnia severity index (ISI) scores by a mean of 5.4 points compared with controls, an effect size comparable to pharmacotherapy 19. The ACP guideline explicitly states: "Clinicians should use cognitive behavioral therapy for insomnia as the initial treatment for chronic insomnia disorder in adults" 18.

Prescribers in Montana often combine CBT-I with suvorexant for the first 8 to 12 weeks, then attempt a gradual medication taper as behavioral strategies take hold. This combined approach has support from a randomized trial showing that CBT-I plus pharmacotherapy produced better long-term outcomes than either intervention alone 20.